Takeda Shaves Off European Subsidiaries And U.S. Jobs On Japanese Approval Day
This article was originally published in PharmAsia News
Daiichi Sankyo's Denosumab and Bayer's Xarelto will soon make their appearance in the Japanese market.
You may also be interested in...
AstraZeneca's Nexium, J&J's Simponi Lead Charge Of New Products To Receive Reimbursement Prices In Japan
TOKYO - A new round of drugs were cleared for market launch in Japan after the latest round of National Health Insurance price listings, and AstraZeneca PLC's blockbuster Nexium (esomeprazole), waning in the West but picking up speed in Asian markets, leads the new wave of products
TOKYO - Bayer AG's anticoagulant Xarelto (rivaroxaban) met its primary endpoint of clinically relevant bleeding - major and non-major bleeding - in a Japanese Phase III trial, in line with the drug's performance in a 14,000+ global Phase III study, easing the path for approval in Japan
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?